Condition
Metastatic Solid Neoplasm
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT03087591Phase 1Completed
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
NCT04167137Phase 1TerminatedPrimary
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Showing all 2 trials